Leveraging GeoVax's Vaccine Expertise To Take On Cancer

September 9, 2019 8:00 AM

ATLANTA, GA / ACCESSWIRE / September 9, 2019 / GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results. Click...

Read more

Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids

September 5, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / September 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from Health Canada to begin a clinical study of its investigational drug, EB02, which the company is developing as a potential treatment for patients with grade I-III internal hemorrhoids. Health Canada reviewed Edesa’s clinical trial application and approved it by issuing a "no objection letter," a...

Read more

Dyadic to Present at Janney Healthcare Conference

September 4, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / September 4, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more

Interface Biologics Announces Sale of Surface Modification Business to Evonik

September 3, 2019 9:00 AM

TORONTO, CANADA / ACCESSWIRE / September 3, 2019 / Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik (EVR:ETK), a German based specialty chemical company with revenues in excess of €13 billion in 2018. The Health Care business line of Evonik, a leading...

Read more

Pieris Pharmaceuticals Announces Changes to Senior Management Team

September 3, 2019 7:30 AM

BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the appointment of Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer and the departure of Allan Reine, M.D., Senior Vice President and...

Read more

Hancock Jaffe Medical Advisory Board Member Dr. Steven Elias Presents at International Union of Phlebology Conference in Krakow, Poland

August 29, 2019 8:31 AM

Presentation Featured VenoValve as Potential Treatment of Chronic Venous Disease IRVINE, CA / ACCESSWIRE / August 29, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on August 25, 2019, Dr. Steven Elias, a member Hancock Jaffe's Medical Advisory Board, made a presentation which featured Hancock Jaffe's VenoValve, at the International...

Read more

Edesa Biotech to Present at H. C. Wainwright Global Investment Conference

August 29, 2019 8:30 AM

TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City. Edesa Presentation Details Date: Monday, September 9, 2019 Time: 2:35 pm Eastern Time Location: Lotte New York Palace Hotel Edesa...

Read more

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

August 29, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Citi 14th Annual Biotech Conference Wednesday, September 4,...

Read more

EBD Group: Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary

August 29, 2019 3:10 AM

Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary CARLSBAD, CA & HAMBURG, GERMANY / ACCESSWIRE / August 29, 2019 / The 25th annual BIO-Europe(R) global life science partnering event will be held November 11-13, 2019, in Hamburg, Germany, supported by regional hosts Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein. The event is expected to bring together 4,400...

Read more

Hancock Jaffe to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

August 27, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / August 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) (NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019 in New York City. H.C. Wainwright 21st Annual Global Investment Conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel in New...

Read more

Molecular Partners Reports Key Financials for H1 19 and Corporate Highlights: EMA has Validated the Marketing Authorization Application for Abicipar; Focus of MP0250 on Multiple Myeloma with Expected Initiation of Ph2 Imid Trial in Q4 19; MP0310 Ph1 Start on Track for H2 19

August 27, 2019 1:00 AM

Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) - Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) - Start of phase 2 trial expected in Q4 19, having received FDA approval MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR-mut NSCLC) in combination with Tagrisso®: Following lift of partial...

Read more

Great Bay Bio's 3D Advisory Board Science Committee Welcomes Another New Arrival

August 26, 2019 10:05 PM

HONG KONG, CHINA / ACCESSWIRE / August 26, 2019 / Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) development of innovative biologics, is pleased to announce that following the successful establishment of the 3D Advisory Board in the middle of this month, the Science Sub-Committee welcomes another new key member, Dr. Mark McHale, to the team. Dr. Mark McHale received...

Read more

ReShape Lifesciences(TM) to Highlight Products at IFSO 24th World Congress

August 22, 2019 8:30 AM

SAN CLEMENTE, CA / ACCESSWIRE / August 22, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be attending the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress, taking place at Ifema Palacio Municipal in Madrid, Spain, from September 3-7, 2019. ReShape Lifesciences™...

Read more

American CryoStem Engages IRB for IND Filling with the FDA

August 22, 2019 7:00 AM

EATONTOWN, NJ / ACCESSWIRE / August 22, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has engaged The Institute of Regenerative Cellular Medicine (IRCM) www.ircm.org to perform the Institutional Review Board (IRB) requirement...

Read more

Dyadic to Present at Four Upcoming Investor Conferences in September

August 21, 2019 4:00 PM

JUPITER, FL / ACCESSWIRE / August 21, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more

Hancock Jaffe Successfully Completes Two Additional VenoValve Implantations for First-in-Man Study

August 20, 2019 8:31 AM

Eight Patients Now Part of First-in-Man Bogota Study IRVINE, CA / ACCESSWIRE / August 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in two additional patients, as part of HJLI’s first-in-man Bogota study. Eight patients have now received VenoValves as part of the initial phase of the first-in-man study. The...

Read more

HemaGenetics Announces Results of Annual General & Special Meeting of Shareholders

August 16, 2019 10:44 AM

VANCOUVER, BC / ACCESSWIRE / August 16, 2019 / HemaGenetics Technologies Corp. (the “Company”) is pleased to announce the results of its annual general & special meeting of its shareholders held on August 9, 2019 at 10 a.m. at Suite 300 - 1055 W. Hastings St., Vancouver, BC, Canada, V6E 2E9 (the “Meeting”). Shareholders of record as of July 12, 2019 voted at the Meeting. The purpose of the Meeting was for shareholders to attend to and vote on...

Read more

Pressure BioSciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

August 15, 2019 9:29 AM

Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double in 2020 Investor Conference Call Scheduled for Thursday, August 15, 2019 at 4:30 PM EDT SOUTH EASTON, MA / ACCESSWIRE / August 15, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

August 15, 2019 7:35 AM

- Building momentum with recent acquisition of innovative XCART platform technology and closing of $15 million underwritten public offering - Corporate strategy shift with entry into the CAR T space positions Company to drive significant value for shareholders - Company executes on initial step in XCART development through recent signing of a research agreement enabling advancement towards its stated goal of establishing an academic...

Read more

Edesa Biotech Reports Quarterly Financial Results

August 14, 2019 4:05 PM

TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on its business. During the quarter, Edesa completed its reverse acquisition and Nasdaq listing, and announced plans to proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which the company is...

Read more